PhD Scientific Days 2023

Clinical Medicine IV.

Examination the interleukin 1A and 1B polymorphisms in medication-related osteonecrosis of the jaw

Előadó neve

Dr. Szentpéteri, Szófia

Neptun code

CAAJ4F

Előadó munkahelye

Semmelweis University, Department of Oro-maxillofacial Surgery and Dentistry, Doctoral School

Előadó telefonszáma

+36305167386

Előadó e-mail címe

szentpeteriszofia@gmail.com

Az előadás címe

Examination the interleukin 1A and 1B polymorphisms in medication-related osteonecrosis of the jaw

Szerző(k) neve és munkahelye

Szófia Szentpéteri dr. 1 , Zsolt Németh Dr. 2, Mihály Vaszilkó Dr. 3
1 Semmelweis University, Department of Oro-maxillofacial Surgery and Dentistry, Doctoral School Budapest
2 Semmelweis University, Department of Oro-maxillofacial Surgery and Dentistry, Budapest
3 Semmelweis University, Department of Oro-maxillofacial Surgery and Dentistry, Budapest

Bemutatás módja

Szóbeli

Szekció

Clinical Medicine IV.

Language of the presentation

English

Preferred session

Clinical Medicine

Összefoglaló szövege

Introductios: The medication-related osteonecrosis of the jaw (MRONJ) is the side effect of the administration of antiresorptive drugs used in the treatment of osteoporosis and bone metastasis of malignant tumors (Ruggiero et al., 2014).
Aims: We examine the single nucleotid polymorphisms (SNPs) of interleukin 1A and 1B (IL-1A-889, IL-1B+3953) in development and prognosis of medication-related osteonecrosis of the jaw (MRONJ).
Methods: In our study we apply DentiGen Parodontitis Test for collecting samples. This test is suitable for sampling oral mucosa cells to ascertain interleukin 1A and 1B single nucleotid polymorphism. The genetic samples were evaluated in the Istenhegyi Genediagnostic Center with DNA-hybridization technic.
In our investigation we have collected samples in patient group and control group. The role of gene polymorphisms in development of the disease is examined by comparing the genetic results of patient group and control group. The investigation of gene polymorphism in the prognosis of the disease is based on stage improvement, recovery and relapses following surgical therapy.
Results: 91 patients were suffering from MRONJ and 59 patients were in the control group. In the patient group 51 (56,04%) patients, in the control group 22 (37,28%) patients had unfavorable allelic variant. We didn’t find any association (p=0,52) between the unfavorable polymorphisms and the development of the MRONJ. In the patient group surgical therapy was used in 79 cases. In this group stage improvement was detected in 78 (98,73%) of the cases, recovery in 67 (88,15%) and relapses in 33 (49,25%). 49 from 79 patients, treated with surgical therapy, had unfavorable allelic variant. We haven’t found any connection between the examined polymorphisms and the stage improvement (p=0,800) or recovery (p=0,990). Significant association (p<0,001) was detected between the relapses and the unfavorable allelic variant.
Conclusion: We found significant association between relapses of MRONJ and the interleukin 1A and 1B polymorphisms. We didn’t find any association between interleukin 1 polymorphisms and the development of MRONJ.
Funding: No funding

University and Doctoral School

Semmelweis University, Károly Rácz Doctoral School of Clinical Medicine

Supervisor

Zsolt Németh Dr., Mihály Vaszilkó Dr.

Publication of my abstract

I do not give consent to the publication of my abstract on the website of the congress.

Kind

Szabad

Status

elfogadva

Accepted presentation method

szóbeli

Előadás fájl jóváhagyás

nem rendelkezett róla

Előadó

4726

Start

12:00

End

12:15

Authors (legacy)

Szófia Szentpéteri dr. 1 , Zsolt Németh Dr. 2, Mihály Vaszilkó Dr. 3
1 Semmelweis University, Department of Oro-maxillofacial Surgery and Dentistry, Doctoral School Budapest
2 Semmelweis University, Department of Oro-maxillofacial Surgery and Dentistry, Budapest
3 Semmelweis University, Department of Oro-maxillofacial Surgery and Dentistry, Budapest